ClinVar Miner

Submissions for variant NM_000179.3(MSH6):c.1168del (p.Asp390fs)

gnomAD frequency: 0.00002  dbSNP: rs753796271
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000491747 SCV000580321 pathogenic Hereditary cancer-predisposing syndrome 2023-06-27 criteria provided, single submitter clinical testing The c.1168delG pathogenic mutation, located in coding exon 4 of the MSH6 gene, results from a deletion of one nucleotide at nucleotide position 1168, causing a translational frameshift with a predicted alternate stop codon (p.D390Ifs*21). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001805110 SCV002051077 pathogenic Hereditary nonpolyposis colon cancer 2023-11-10 criteria provided, single submitter clinical testing Variant summary: MSH6 c.1168delG (p.Asp390IlefsX21) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 2e-05 in 251000 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1168delG has been reported in the literature in individuals with a personal or family history of Lynch Syndrome-related cancers (e.g., Wu_2015, Feliubadalo_2019). These data indicate that the variant is very likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 30927264, 25954033). Two submitters have reported clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Mendelics RCV002248719 SCV002517639 pathogenic Endometrial carcinoma 2022-05-04 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV003449326 SCV004187081 pathogenic Lynch syndrome 5 2023-08-11 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.
Invitae RCV003758797 SCV004519703 pathogenic Hereditary nonpolyposis colorectal neoplasms 2024-01-24 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Asp390Ilefs*21) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). This variant is present in population databases (rs753796271, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with undergoing testing for Lynch syndrome (PMID: 30927264). ClinVar contains an entry for this variant (Variation ID: 218051). For these reasons, this variant has been classified as Pathogenic.
All of Us Research Program, National Institutes of Health RCV004003463 SCV004843037 pathogenic Lynch syndrome 2023-05-03 criteria provided, single submitter clinical testing The c.1168del (p.Asp390Ilefs*21) variant in the MSH6 gene is located on the exon 4 and is predicted to cause reading frame shift that introduces a premature translation termination codon (p.Asp390Ilefs*21), resulting in an absent or disrupted protein product. The variant has been reported in 2 unrelated individuals affected with Lynch syndrome (PMID: 27903930, 30383610). Loss-of-function variants located downstream to this position have been reported in individuals with Lynch syndrome-associated cancer (PMID: 20028993). The variant is rare in the general population according to gnomAD (5/251000). Therefore, the c.1168del (p.Asp390Ilefs*21) variant of MSH6 has been classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.